{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".007","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"The number of subjects with severe VOD / SOS; severity staged according to criteria set forth by McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267. Assessed within the first 100 days post transplant.","groups":[{"description":"Busulfan AUC Level 1: 6000 +/- 600 uM-min Fludarabine 40 mg/m\\^2 I.V. over 1 hour","id":"OG000","title":"AUC 6000"},{"description":"Busulfan AUC Level 2: 7500 +/- 750 uM-min Fludarabine 40 mg/m\\^2 I.V. over 1 hour","id":"OG001","title":"AUC 7500"},{"description":"Busulfan AUC Level 3: 9000 +/- 900 uM-min Fludarabine 40 mg/m\\^2 I.V. over 1 hour","id":"OG002","title":"AUC 9000"}],"paramType":"NUMBER","populationDescription":"Intent to treat","reportingStatus":"POSTED","timeFrame":"100 days","title":"Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)","type":"SECONDARY","unitOfMeasure":"participants"}